Aumilto Silva, Medical Oncologist and Clinical Research at Hospital Santa Catarina Paulista, shared a post on X:
“New real-world study in early HER2+ and TNBC after neoadjuvant therapy.
In this study pCR remained the strongest prognostic marker. In 863 patients, 3-year RFS was 98% with pCR vs 79% with residual disease; 3-year OS was 100% vs 88%. In HER2+, 3-year RFS was 99% with pCR vs 87% with RD; in TNBC, 97% vs 72%.
Baseline cT/cN/subtype predicted worse outcomes mainly in patients with residual disease. Among patients achieving pCR, baseline stage was not significantly associated with RFS or OS in this cohort.
In this study pCR appears to largely mitigate the adverse effect of initial tumor burden, but residual disease still identifies a clearly higher-risk population needing escalation/novel strategies.”
Title: Impact of pathologic response and individual prognosis after neoadjuvant treatment in patients with early HER2+ and triple-negative breast cancer
Authors: Chiara Corti, Tianyu Li, Alyssa R. Martin, Melissa E. Hughes, Tonia Parker, Tyzaire S. Duporte, Giuseppe Curigliano, Tari A. King, Elizabeth A. Mittendorf, Nancy U. Lin, Nabihah Tayob, Sara M. Tolaney
Read the Full Article.
Other articles featuring Aumilto Silva on OncoDaily.